Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan.
Intest Res
January 2025
Office of the Chief Medical Officer, Johnson & Johnson, Raritan, NJ, USA.
Background/aims: There are few studies that comprehensively report real-world persistence for first-line advanced therapies used to treat inflammatory bowel disease. We aimed to describe persistence of first-line advanced therapies among incident biologic or Janus kinase inhibitor users with inflammatory bowel disease.
Methods: Retrospective cohort study using the Japan Medical Data Center database from January 1, 2010, until September 30, 2022.
Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study.
J Crohns Colitis
December 2024
Copenhagen University Hospital - Amager and Hvidovre, Gastrounit, Medical Section, Hvidovre, Denmark.
Background And Aims: Existing findings on outcomes of anti-tumor-necrosis-factor (TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based on retrospective studies. We aimed to investigate real-world outcomes of anti-TNF therapy and predictors thereof in a prospective IBD cohort.
Methods: In a Danish multicenter cohort of adult bio-naïve patients with IBD treated with anti-TNF, we assessed clinical response and remission to induction therapy using clinical disease activity scoring indices at week 14.
Development of Behçet's disease on maintenance therapy for autoimmune hepatitis.
BMJ Case Rep
December 2024
Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Behçet's disease is a clinical diagnosis with variable presentations. Liver involvement is rare in the absence of vascular complications. We describe a patient diagnosed with Hashimoto's thyroiditis and autoimmune hepatitis on azathioprine who developed extensive aphthous ulcers approximately 10 years later.
View Article and Find Full Text PDFInadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study.
Clin Gastroenterol Hepatol
December 2024
TMDU Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address:
Background And Aims: While biologic therapy has revolutionized the treatment of Crohn's disease (CD), surgery remains unavoidable in cases involving ileal complications. We aimed to evaluate the efficacy of biologics on proximal ileal lesions using balloon-assisted enteroscopy (BAE).
Methods: This open-label multicenter prospective study was conducted at tertiary referral centers in Japan.
Oral manifestations of Crohn disease managed with ustekinumab: A case report.
J Am Dent Assoc
December 2024
Background: The authors reviewed a case involving the orofacial manifestations of Crohn disease (CD) in an adolescent whose treatment was ultimately managed with a newer class of biologic drug agent, ustekinumab (Stelara, Janssen Biotech). CD is a chronic inflammatory condition affecting the gastrointestinal tract that often causes extraintestinal complications. The underlying etiology of CD involves genetic, environmental, and local factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!